[ad_1]
The vaccine, tested on humans and monkeys, showed a "robust immune response" in healthy people and protected more than 67% of animals
The new vaccine is made from a mosaic of combinations of different types of HIV and AIDS.
access_time
July 7, 2018, 4:13 pm – Posted Jul 7, 2018, A new vaccine against HIV has promising results . promising results . According to a study published Friday in the scientific journal The Lancet healthy adults who received the vaccine have produced "robust immune responses" against HIV. Already the monkey test showed that 67% of the vaccinated animals were protected against the virus
Challenge
The development of an effective vaccine against the disease is a challenge for specialists and researchers. Despite the advances of recent decades in the treatment of HIV, there is still no cure or vaccine that can provide protection against the virus.
The great difficulty in producing an effective HIV vaccine is the wide variety of viral strains. , in addition to its strong mutation potential. Previous attempts, which have been limited to producing immunizers from a specific type of virus, have failed.
The potential success of the current vaccine lies precisely in its composition. Its development is a kind of mosaic made with parts of different types of HIV virus. However, induction of the immune response in human tests does not yet mean that people who have received the vaccine would not be infected if they had been in contact with HIV.
"The challenges of developing an HIV vaccine are unprecedented – the ability to induce an immune response to HIV does not necessarily mean that the vaccine will protect humans from infection," said Dan Barouch, Professor of Medicine at Harvard Medical School in the United States and the study coordinator.The research team led by researcher Dan H. Barouch applied a standard dose of various combinations of mosaic vaccine to 393 Healthy people, aged 18 to 50. The objective of the study was to test the safety, tolerance and ability of the vaccine to trigger immune responses.
Participants were randomly selected from the United States, Rwanda, Uganda, South Africa and Thailand, each receiving four doses of the vaccine – or placebo – over a 48-week period (approximately one year). showed that all the tested vaccine combinations caused the immune system participants to respond to HIV. In the animal study, 72 randomly selected rhesus monkeys were vaccinated with the same combinations tested in humans. These animals were then infected with simian simian virus simian immunodeficiency virus. The combination that was able to generate the best immune response in humans was also able to protect 67% of animals against the virus.
Michael Brady, Medical Director of Terrence Higgins Trust, a British charity that fights HIV, "It's important to be cautious and clear that there's still a lot of work to be done before and # 39, an effective HIV vaccine becomes available. "
is the fifth HIV vaccine tested in humans. Among them, only one, tested in Thailand, has reduced the risk of HIV infection. However, the effectiveness of only 31% was not sufficient for the approval of the vaccination.
The next step in the study will be to apply treatment to 2,600 women in South Africa who are at risk of contracting the disease. It is expected that more conclusive results will be presented by 2022.
About 37 million people worldwide are living with HIV and it is estimated that 1.8 million people are infected each year. year. Among the advances in the fight against the disease already achieved so far, there is the pre-exposure prophylaxis, called Prep, which can prevent HIV infection because it is taken regularly.
Source link
